Medical support for alcohol reduction
Changing your drinking habits can be challenging, particularly when alcohol has become part of your daily routine or a way of managing stress, anxiety, sleep difficulties or difficult emotions. For some people, a combination of medical assessment, behavioural support and medication can help make changes more achievable.
Understanding the role of medical treatment
Our approach is centred on understanding your individual circumstances, discussing your goals and identifying appropriate treatment options. These may include support aimed at reducing alcohol consumption, preventing a return to heavy drinking or helping you maintain abstinence.
This follows the approach described by NICE and the Department of Health and Social Care: treatment based on assessment, agreed goals, appropriate medication when indicated and monitoring of outcomes.
How can medication help?
Alcohol affects several chemical signalling systems in the brain, including pathways involved in motivation, reward, learning and reinforcement. These systems can contribute to the desire to drink and the repetition of drinking behaviours.
Some medicines used in alcohol treatment work by influencing these processes. They do not remove the underlying causes of alcohol-related difficulties, and they do not replace the need for appropriate psychological or behavioural support.
Medications that may be offered
Where a clinician decides that medication is suitable, it may be one of the following. Which medicine, if any, is right for you is decided after your assessment.
- Naltrexone: an opioid receptor antagonist. By blocking opioid receptors involved in alcohol-related reward signalling, it can reduce the rewarding effects of drinking and help some people reduce heavy drinking or relapse risk. Oral naltrexone is a licensed treatment for alcohol dependence in the UK.
- Nalmefene: also an opioid receptor antagonist, licensed in the UK to reduce alcohol consumption in adults with alcohol dependence who drink at a high risk level, have no physical withdrawal symptoms and do not need immediate withdrawal treatment. It is taken alongside ongoing psychological support.
- Acamprosate: licensed in the UK to help people with alcohol dependence stay alcohol-free once they have stopped drinking. It is usually started as soon as possible after assisted withdrawal.
- Baclofen: a muscle relaxant that is not licensed in the UK for alcohol dependence. It is only considered as off-label treatment where a clinician judges it appropriate, with a clear clinical justification and informed discussion with you.
Prescribing outside a medicine's licensed indication needs an appropriate clinical justification, consideration of the evidence and alternatives, informed discussion with you, and documentation in line with professional guidance. A prescription is not guaranteed.
No medicine for alcohol reduction makes a person sober, eliminates intoxication or makes alcohol consumption safe. None treats acute alcohol withdrawal, and none guarantees abstinence or removes the need for ongoing support.
Why is an individual medical assessment important?
Alcohol-related treatment needs vary considerably between individuals. Drinking patterns, physical health, liver function, current medicines, previous withdrawal symptoms and personal treatment goals all influence which options may be appropriate.
A clinical assessment helps determine whether treatment can safely be provided in a private outpatient setting, or whether a GP, specialist alcohol service or hospital-based assessment would be more suitable.
Who may benefit from medical treatment?
A clinician may consider medication for an adult with alcohol-related problems when the potential benefits outweigh the risks and the treatment fits the person's goals. Potentially relevant circumstances include:
- Repeated episodes of heavy drinking after attempts to reduce or stop.
- Difficulty controlling drinking once alcohol consumption begins.
- A desire to reduce the likelihood of returning to heavy drinking.
- A need for relapse-prevention support following medically assisted withdrawal.
- A preference for medication alongside appropriate psychological treatment.
These are reasons to consider assessment, not automatic indications for prescribing. No single drinking pattern or symptom reliably predicts who will respond best. Medication should not be presented as a way to continue drinking without harm.
Medical assessment and blood tests
Your assessment covers your alcohol history, withdrawal risk, medical history, a review of all your medicines, other substance use, pregnancy and breastfeeding where relevant, blood tests and a plan for follow-up. NICE recommends a comprehensive medical assessment before starting oral naltrexone, including baseline urea and electrolytes and liver function tests. Blood tests may include:
- Liver function tests (LFTs), including relevant enzymes and bilirubin, to assess liver health.
- Urea and electrolytes (U&Es) and a renal profile, to assess kidney function and electrolyte balance.
- A full blood count (FBC), to identify abnormalities such as anaemia that may be relevant to harmful alcohol use or other health conditions.
Results are interpreted in context. Normal blood tests do not exclude all alcohol-related disease, and abnormal results do not have a single universal threshold for prescribing. Further tests, repeat investigations or specialist advice may be necessary.
Important safety checks
Medication is not suitable for everyone. Before anything is prescribed, your clinician checks:
- Opioid use: naltrexone and nalmefene block opioid receptors. In someone who is opioid-dependent, they can precipitate severe, potentially life-threatening withdrawal, and they can block opioid painkillers. Your assessment includes prescribed and non-prescribed opioids, including codeine, morphine, methadone, buprenorphine and opioid-containing combination products.
- Liver and kidney function: acute hepatitis, liver failure, severe hepatic impairment and severe renal impairment need particular attention. Less severe impairment is assessed individually, with monitoring where appropriate.
- Pregnancy and breastfeeding: discussed confidentially, weighing potential benefits and risks against alternatives.
- Allergies and other medicines: including any future need for surgery, emergency pain relief or opioid painkillers.
If you take medication for alcohol reduction, tell any healthcare professional treating you, including in an emergency.
If you may be physically dependent on alcohol
Seek medical advice before reducing or stopping. A history of withdrawal seizures, delirium tremens or significant physical illness may need hospital-based care rather than a routine private outpatient consultation.
Side effects and safety-netting
You receive the patient information leaflet for any medicine prescribed, and advice on what to do if you have an adverse effect. Possible adverse effects include nausea, abdominal discomfort, vomiting, headache, dizziness, fatigue, sleep disturbance and anxiety.
Liver-related adverse effects need particular attention. Seek prompt medical assessment if you develop symptoms suggestive of liver injury, such as jaundice, dark urine or significant unexplained abdominal symptoms. You should also understand that:
- Medication does not reverse alcohol intoxication.
- It does not treat acute alcohol withdrawal.
- Attempts to overcome opioid blockade with large opioid doses can be fatal.
- Emergency clinicians must be told about current or recent naltrexone or nalmefene use.
- Suspected adverse drug reactions can be reported through the MHRA Yellow Card scheme.
Why psychological support remains important
Medication works best within a broader, individualised care plan. Your clinician explores the situations in which you drink, the functions alcohol serves in your life and the barriers you face when trying to change. Potential interventions include:
- Motivational interviewing to explore ambivalence and strengthen commitment to change.
- Cognitive behavioural therapy to identify triggers, thoughts and behaviours associated with drinking.
- Strategies for cravings, stress, social pressure and high-risk situations.
- Relapse-prevention planning and support following a lapse.
- Appropriate family, community or specialist alcohol-service involvement.
Monitoring and review
Before treatment begins, you and your clinician agree measurable goals: reducing heavy-drinking days, reducing total alcohol consumption, improving control over drinking, maintaining abstinence, or improving alcohol-related health and functioning. At follow-up, your clinician reviews:
- Progress against the agreed goals.
- Alcohol intake and any return to heavy drinking.
- Side effects and adherence.
- Changes in physical health or mental health.
- New medicines, opioid exposure or upcoming procedures.
- Whether repeat blood tests, further investigations or specialist referral are needed.
- Whether the current treatment remains appropriate.
UK guidance describes a common treatment period of six months, with possible extension to 12 months when there is ongoing benefit, and stopping and reviewing treatment after four to six weeks if a person continues drinking and has had no benefit.
A whole-person approach
Effective alcohol care can include:
- A confidential assessment of drinking patterns and health.
- An agreed plan for reducing alcohol-related harm or working towards abstinence.
- Review of appropriate medical treatment options.
- Behavioural strategies to manage triggers and cravings.
- Monitoring of progress, side effects and physical health.
- Referral to additional services when a higher level of care is required.
Medication is one possible part of treatment, not a guaranteed solution. The aim is to help each person make informed, sustainable changes while prioritising safety and wellbeing. We will not promise that a prescription or medication will make you better, but we will support you throughout.
Professional references
Our clinical protocol follows these UK sources:
- NICE guideline CG115, Alcohol-use disorders: diagnosis, assessment and management.
- Department of Health and Social Care, Clinical guidelines for alcohol treatment, chapter 10: pharmacological interventions.
- MHRA product information: the Summary of Product Characteristics and Patient Information Leaflet for each medicine prescribed.
- British National Formulary (BNF) monographs.
